RESUMO
Cutaneous rash is one of the commonest adverse events associated with lamotrigine. We assessed whether the risk is increased in patients receiving concomitant valproate therapy in a population of 103 adult patients with intractable epilepsy, who had lamotrigine added to their treatment. Of the 33 patients taking valproate, 10 (30 per cent) developed a rash, whilst of the 70 not taking valproate, only 6 (8 per cent) developed a rash. This suggests a significantly higher risk of cutaneous rash when starting lamotrigine in patients already taking valproate (pAssuntos
Humanos
, Masculino
, Feminino
, Adolescente
, Adulto
, Pessoa de Meia-Idade
, Anticonvulsivantes/efeitos adversos
, Toxidermias/etiologia
, Ácido Valproico/administração & dosagem
, Ácido Valproico/uso terapêutico
, Anticonvulsivantes/administração & dosagem
, Triazinas/administração & dosagem
, Triazinas/efeitos adversos